You are here
Scott Aaronson, M.D., MD
Dr. Aaronson is Director of Clinical Research Programs at Sheppard Pratt Health System in Baltimore, Maryland, where he has been responsible for developing a research program dedicated to the development of medications, devices and genetic tests for the treatment of illnesses across the spectrum of psychiatric disorders. He is Principal Investigator for studies in various phases and presentations of affective illness, psychosis and dementia. He has particularly been involved with the development of new strategies, both pharmacologic and device based, to alleviate the symptoms in treatment resistant mood disorders. Dr. Aaronson earned his medical degree with honors from Harvard Medical School in Boston and completed a residency in Psychiatry at McLean Hospital in Belmont, Massachusetts. He is a Clinical Associate Professor of Psychiatry at the University of Maryland, School of Medicine. He is a fellow of the American College of Psychiatrists.
He is a valued member of the Sheppard Pratt community where he provides expert consultation across the system of care for patients with difficult to treat mood and psychotic disorders.
He has published numerous articles on his research and contributed a chapter to a book published in 2014 on Transcranial Magnetic Stimulation by Oxford University Press.
Dr. Aaronson is board-certified in Psychiatry and he is a member of several professional organizations, including Distinguished Fellowship in the American Psychiatric Association and the Maryland Psychiatric Society for which he served as President. He also is Chairman of the Data Safety and Management Board for the Maryland Psychiatric Research Center.